WE Initiate Science & Technology Value,
Always for Caring

WESTVAC

Extensively explore and innovate to prevent and fight human disease

International Leading Vaccine and Immunotherapy Platform

WE
CARE

Creation Acceleration Responsibility Excellence

Media

2023-08-28

With the emergence of the COVID-19 EG.5 variant, how can the public protect themselves effectively?
The EG.5 variant is a descendant lineage of XBB.1.9.2 (a sublineage of Omicron) and was first reported in Indonesia on February 17, 2023.
Read More
2023-08-07

All four key indicators of SARS-CoV-2 in the United States have increased, suggesting the early stages of a new wave of the pandemic
In July 2023, according to data from the Centers for Disease Control and Prevention (CDC) in the United States, four key indicators including monitoring of SARS-CoV-2 virus concentration in wastewater samples, COVID-19 positivity rate, emergency department visits, and hospitalizations have all increased.
Read More
2023-08-01

Breaking News! China National Health Commission Released "Implementation Plan for COVID-19 Vaccination for Key Groups in the Near Future"
To further prepare for the response to the COVID-19 pandemic during the upcoming autumn and winter seasons and ensure the maximum protection of people's lives and health, on July 31, 2023, the Joint Prevention and Control Mechanism of the State Council for Novel Coronavirus Pneumonia issued the "Implementation Plan for COVID-19 Vaccination for Key Groups in the Near Future" (hereinafter referred to as the "Implementation Plan").
Read More

About Us

WestVac BioPharma Co., Ltd. is an innovative biopharmaceutical enterprise integrating vaccine R&D, production and sales, including WestVac Biopharma located in Chengdu and WestVac Biopharma (Guangzhou), a wholly-owned subsidiary company of WestVac Biopharma. With the continuous investment and support of many powerful shareholders -- CICC Capital, Shanghai Pharma, Haier Biomedical and so on, WestVac BioPharma has been successfully selected into the list of unicorn companies for two consecutive years from 2021 to 2023.

In terms of production, quality, operations management, etc., WestVac Biopharma has introduced top talents from well-known domestic and international vaccine companies, established a complete production and quality management system, has more than 500 employees to ensure mass production of vaccines can proceed smoothly.

WestVac Biopharma has a mature insect cell expression platform, mRNA vaccine platform, novel adjuvant platform, bacterial vaccine platform, tumor vaccine and immunotherapy platform, with more than 20 pipelines including COVID-19 vaccine, multivalent influenza vaccine, respiratory syncytial virus vaccine, herpes virus vaccine, tumor immunity preparations.

Phase III clinical trials of the first generation Recombinant COVID-19 Vaccine (Sf9 cells)-Coviccine, have been rolled out globally in multiple countries, with nearly 40,000 subjects enrolled and vaccinated. The clinical trials in Japan for marketing purpose have been concluded, which is the first Chinese COVID-19 vaccine that entered clinical trials in a developed country. Study results show that the vaccine has good safety and immunogenicity, fully demonstrating the advantages and characteristics of the recombinant protein vaccine technology route. On December, 2022, Coviccine® was approved for emergency use (EUA) by relevant authorities in China. It has been delivered to more than 20 provinces of China for vaccination. WestVac Biopharma constantly aiming at evolvement of SARS-CoV-2, Recombinant Variant COVID-19 Vaccine (Sf9 Cell) against Omicron variants has been developed, Phase I/II clinic trials of this vaccine has been approved in China and Mexico. Study results show that it can induce a variety of animals to produce very high titer of neutralizing antibodies against Omicron, Delta variants. 

The XBB.1.5 variant had gradually become the major circulating variant in various parts of the world by the beginning of 2023. the scientific team of WestVac Biopharma/West China Medical Center, Sichuan University overcame all hurdles and successfully developed Recombinant Bivalent COVID-19 (XBB + Prototype Strain) Protein Vaccine (Sf9 cell) Coviccine ® Bivalent and Recombinant Trivalent COVID-19 (XBB + BA.5 + Delta variant) Trimeric Protein Vaccine (Sf9 cell). 

On June 8th, 2023, Coviccine® Trivalent XBB.1.5-Recombinant COVID-19 Trivalent（XBB.1.5+BA.5+Delta）Protein Vaccine (Sf9 cell) developed by WestVac Biopharma/ West China Medical Center, Sichuan University was approved for EUA by relevant authorities in China. This is the first COVID-19 vaccine in the world approved for EUA against XBB descendent lineages of SARS-CoV-2. It demonstrates that China is leading the world in the development of COVID-19 vaccines.  

WestVac Biopharma leverages the rapid response of the insect cell expression platform on constructing the vector for Coviccine® Trivalent XBB.1.5-Recombinant COVID-19 Trivalent (XBB.1.5+BA.5+Delta) Protein Vaccine (Sf9 Cell), which is of high purity and high quality for human use. The subunit vaccine antigen is precisely designed based on the structure of the targeting S-RBD and HR proteins of the COVID-19 subvariants XBB.1.5 and BA.5 and self-assembled into stable trimeric protein particles with squalene-based oil-in-water emulsion adjuvant added after purification and mixing. This novel adjuvant significantly raises the titer of neutralizing antibodies, which enables the trimeric protein vaccine to induce a higher level T-cell immune response. Studies have shown that Coviccine® Trivalent XBB.1.5 induced a high titer of neutralizing antibodies against multiple subvariants, including Omicron subvariants XBB.1.5, XBB1.16, XBB1.9.1, XBB.2.3, BA.5, BF.7, BQ.1, BA.2.75, 14 days after injection of this product, the protective efficacy against XBB.1, XBB.1.5, XBB1.9 is 93.28% with an excellent safety profile, demonstrating that it is a broad-spectrum COVID-19 vaccine against multiple prevalent subvariants locally and internationally.

WestVac Biopharma Co., Ltd. is located in in Chengdu Tianfu International Biological City, has completed construction of 5,000-litre and 3,000-litre insect cell recombinant protein vaccine production lines with an annual production capacity of 100 million doses. The GMP production lines were well established with the “Drug Production License" in place. WestVac Biopharma (Guangzhou) is located in Guangzhou Economic Development Zone, has completed scale-up construction of insect cell recombinant protein vaccine production lines with an annual production capacity of 100 million doses.

WestVac Biopharma has established a sound communication mechanism with many international organizations such as the World Health Organization (WHO), Bill & Melinda Gates Foundation, PATH, The Coalition for Epidemic Preparedness Innovations (CEPI). In the future, WestVac Biopharma will grow into a world leading vaccine and immunotherapy platform in line with the corporate philosophy of "We Initiate Science & Technology Value, Always for Caring", seek innovation in the prevention and overcome of human diseases, bring innovative vaccines and immunotherapies from China to the world for the benefit of mankind.

Read More

Product R＆D

WestVac Biopharma has mature insect cell expression platform, mRNA vaccine platform, novel adjuvant platform, bacterial vaccine platform, oncology vaccine and immunotherapy platform, and has more than 20 product pipelines including a series of COVID-19 vaccines, multivalent influenza vaccines, respiratory syncytial virus vaccines, herpes virus and oncology immune preparations.

After the outbreak of the COVID-19 epidemic in early 2020, with the full support of governments at all levels, West China Medical Center of Sichuan University and WestVac Biopharma actively took part in the scientific and technological actions to fight against epidemic, and achieved many breakthroughs through their efforts. West China Medical Center, affiliated to Sichuan University, is the largest national-level medical center in western China. Its State Key Laboratory of Biotherapy is the only State Key Laboratory in the country with the theme of "biotechnology treatment of major human diseases". There are more than 150 R&D personnel with multidisciplinary backgrounds, including 13 Changjiang/Young Changjiang Scholars and 18 winners of the National Outstanding Youth Fund. Published more than 30 high-level papers in journals such as Nature, Science, Nat.Commun, STTT, in particular, the first article on COVID-19 vaccine was published in Nature magazine（Nature, 2020, 586: 572-577）and applied for more than 50 domestic and foreign patents.

WestVac Biopharma's recombinant COVID-19 vaccine has won project approval and funding by vaccines team of State Council's Joint Prevention and Control Mechanism for five consecutive times, from vaccines targeting prototype strains to vaccines targeting variants, to multi-component multivalent vaccines, to COVID-19 vaccine against XBB variant, continues to update technology to fight consecutive variants, providing innovative options for the normalization of the epidemic management and the vaccination of COVID-19 vaccine, contributing China's strength to the global fight against COVID-19 epidemic.

On July 29, 2020, the R&D team of WestVac Biopharma published the first research paper on the COVID-19 vaccine in "Nature" magazine , and adopted an innovative recombinant protein technology--- China's first Recombinant Protein COVID-19 Vaccine (Sf9 cells)—Coviccine®, introduces the gene of the COVID-19 virus into insect cells, prepares the S protein of the COVID-19 virus, induces human body to produce antibodies to block the virus infection, and has achieved large-scale production. The phase I/II clinical trial of Coviccine® was completed in June 2021. At present, the global multi-center phase III clinical trial has been carried out in many countries, and the enrollment and vaccination of nearly 40,000 subjects have been completed, and completed clinical trials in Japan for the purpose of marketing, this is the first COVID-19 vaccine in China to enter clinical trials in developed countries. In February 2023, WestVac Biopharma has obtained Japan's "Certification of Foreign Manufacturers of Pharmaceuticals-Certification of Pharmaceutical Biological Preparations", which shows that WestVac Biopharma has reached the international advanced level in this field. The results of the Coviccine ® test show that the vaccine has good safety and immunogenicity, which fully reflects the advantages and characteristics of the technical route of recombinant protein vaccines. In December 2022, with the approval of relevant national departments, Coviccine®-Recombinant COVID-19 Vaccine (Sf9 Cell) was approved for EUA, and it has been delivered and supplied for vaccination in more than 20 provinces in China. WestVac Biopharma continues to follow up the epidemic trend of the COVID-19 virus, and has developed a Recombinant COVID-19 Trivalent Vaccine (Sf9 cell) against Omicron, which has obtained clinical approval and entered clinical research. It has good protective efficacy against COVID-19 caused by Omicron variant.

The XBB.1.5 variant had gradually become the major circulating variant in various parts of the world by the beginning of 2023. the scientific team of WestVac Biopharma overcame all hurdles and develop the recombinant bivalent COVID-19 (XBB + prototype strain) protein vaccine (Sf9 cell) Coviccine ® bivalent and recombinant trivalent COVID-19 (XBB + BA.5 + Delta variant) trimeric protein vaccine (Sf9 cell). 

On June 8th, 2023, Coviccine® Trivalent XBB.1.5-Recombinant COVID-19 Trivalent（XBB.1.5+BA.5+Delta）Protein Vaccine (Sf9 cell) was approved for EUA by relevant authorities in China. This is the first COVID-19 vaccine in the world approved for EUA against XBB descendent lineages of SARS-CoV-2. It demonstrates that China is leading the world in the development of COVID-19 vaccines.  

WestVac Biopharma leveraged the rapid response of the insect cell expression platform on constructing the vector for Coviccine® Trivalent XBB.1.5-Recombinant COVID-19 Trivalent (XBB.1.5+BA.5+Delta) Protein Vaccine (Sf9 Cell), which is of high purity and high quality for human use. The subunit vaccine antigen is precisely designed based on the structure of the targeting S-RBD and HR proteins of the COVID-19 subvariants XBB.1.5 and BA.5 and self-assembled into stable trimeric protein particles with squalene-based oil-in-water emulsion adjuvant added after purification and mixing. Novel adjuvant significantly raises the titer of neutralizing antibodies, which enables the trimeric protein vaccine to induce a higher level T-cell immune response. Studies have shown that the vaccine induced a high titer of neutralizing antibodies against multiple subvariants, including Omicron XBB.1.5, XBB1.16, XBB1.9.1, XBB.2.3, BA.5, BF.7, BQ.1, BA.2.75, 14 days after injection of this product, the protective efficacy against XBB.1, XBB.1.5, XBB1.9 is 93.28% with an excellent safety profile, demonstrating that it is a broad-spectrum COVID-19 vaccine against multiple prevalent subvariants locally and internationally.

In addition, in order to improve the safety and accessibility of the vaccine, WestVac Biopharma has also developed a nasal spray recombinant mutant COVID-19 vaccine (Sf9 cells) against variants, which improves the protection efficiency by inducing nasal mucosal immunity. Based on a large number of studies, a nasal spray formulation that can induce a strong immune response has been screened, which can induce a high level of neutralizing antibodies.WestVac Biopharma is also simultaneously carrying out the research and development of new oral anti- COVID-19 virus drugs , and the current test results show that it has good in vivo safety and activity.

Read More

Commercialization

WestVac BioPharma Co., Ltd. is an innovative biopharmaceutical enterprise integrating vaccine R&D, production and sales, including WestVac Biopharma located in Chengdu and WestVac Biopharma (Guangzhou), a wholly-owned subsidiary company of WestVac Biopharma. WestVac Biopharma has a mature insect cell expression platform, mRNA vaccine platform, novel adjuvant platform, bacterial vaccine platform, oncology vaccine and immunotherapy platform. It is committed to develop and produce a variety of innovative vaccines and immunotherapy products.

WestVac Biopharma Co., Ltd. is located in in Chengdu Tianfu International Biological City, has completed construction of 5,000-litre and 3,000-litre insect cell recombinant protein vaccine production lines with an annual production capacity of 100 million doses. The GMP production lines were well established with the “Drug Production License" in place. WestVac Biopharma (Guangzhou) is located in Guangzhou Economic Development Zone, has completed scale-up construction of insect cell recombinant protein vaccine production lines with an annual production capacity of 100 million doses.

In terms of production, quality, operations management, etc., WestVac Biopharma has introduced top talents from well-known domestic and international vaccine companies, established a complete production and quality management system, has more than 500 employees to ensure mass production of vaccines can proceed smoothly.

WestVac Biopharma has established a sound communication mechanism with many international organizations such as the World Health Organization (WHO), Bill & Melinda Gates Foundation, PATH, The Coalition for Epidemic Preparedness Innovations (CEPI).

In the future, WestVac Biopharma will grow into a world leading vaccine and immunotherapy platform in line with the corporate philosophy of "We Initiate Science & Technology Value, Always for Caring", seek innovation in the prevention and overcome of human diseases, bring innovative vaccines and immunotherapies from China to the world for the benefit of mankind.

Read More